Attached files
| file | filename |
|---|---|
| EX-99.1 - FENNEC PHARMACEUTICALS INC. | v205915_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of
report (Date of earliest event reported) December 17,
2010
|
Adherex Technologies
Inc.
|
|
(Exact
Name of Registrant as Specified in Its
Charter)
|
|
Canada
|
001-32295
|
20-0442384
|
||
|
(State
or Other Jurisdiction
of
Incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
501
Eastowne Drive, Suite 140, Chapel Hill , North Carolina 27514
(Address
of Principal Executive Offices) (Zip Code)
919-636-4530
(Registrant’s
Telephone Number, Including Area Code)
Not
applicable.
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction
A.2. below):
|
¨
|
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
¨
|
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
|
Item
8.01
|
Other
Events
|
On
December 17, 2010, Adherex Technologies, Inc. (the “Company”) issued a press
release in response to recent stock trading activity. The full text
of the press release is furnished as Exhibit 99.1.
Exhibits
|
99.1
|
Press
Release issued by Adherex Technologies, Inc. dated December 17,
2010.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
Dated: December
17, 2010
|
Adherex
Technologies Inc.
|
||
|
By:
|
/s/ Robert Andrade
|
||
|
Chief
Financial Officer
|
|||